A New Direction in PAH: A Potential Therapy for Rebalancing BMPR2 Signaling

Thank you

Thank you for joining us today. Industry Innovations Webinars are archived on the ATS YouTube channel under the Industry Innovation playlist.

Expect a brief satisfaction survey via email in the next few days. Your feedback is appreciated as it helps improve programming for the future.

Description

Despite multiple treatment options, patients with PAH still face a devastating and progressive disease. This program will focus on the imbalances in BMPR2 and activin receptor signaling that may drive PAH progression. A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential disease modification.

Disclaimer: Opinions expressed, and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.

Webinar is sponsored by Acceleron. By registering for this webinar, you understand your information will be shared with the sponsor.

No CEU's or credits are provided for this webinar.

Contributors

Vallerie McLaughlin, MD

Vallerie V. McLaughlin, MD, is the Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular of the UMMG, Director of the Pulmonary Hypertension (PH) Program, and Associate Chief of Cardiovascular Medicine at the University of Michigan, Ann Arbor. She is a Fellow of the American College of Cardiology, the American College of Chest Physicians and the American Heart Association, and is a member of the American Thoracic Society. She has served as Chair of the American Heart Association “Women in Cardiology” Committee and as a member of the American College of Cardiology Scientific Sessions Program Committee. Professor McLaughlin is a past Chair of the Scientific Leadership Council of the Pulmonary Hypertension Association, past Editor-in-Chief of Advances in Pulmonary Hypertension and past Chair of the Pulmonary Hypertension Association Board of Trustees. She was Chair of the American College of Cardiology/American Heart Association Clinical Expert Consensus Document on PH. She was inaugurated as a charter member into the Clinical Excellence Society at the University of Michigan and founding member of the World Symposia on Pulmonary Hypertension Association. Her research interests focus on PH

Thank you

Description

Contributors

Vallerie McLaughlin, MD